跳至主要内容
临床试验/NCT04576754
NCT04576754已完成不适用

Postpartum Depression Pivotal Test: Randomized Clinical Trial of WB001

Woebot Health2 个研究点 分布在 1 个国家目标入组 83 人开始时间: 2020年11月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
83
试验地点
2
主要终点
Hamilton Depression Rating Scale for Depression (HAMD)

研究概览

简要总结

The purpose of the present randomized controlled study is to investigate if there is a difference in postpartum depression symptoms among participants assigned to :

  1. an automated conversational agent based on the most researched and scientifically validated psychotherapies, primarily Cognitive Behavioral Therapy (CBT), and accessible via an iOS and Android application, or to
  2. a comparison condition without CBT and conversation, though still delivered in an interactive smartphone application that is accessible anytime of day.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women aged 18-45 years who had onset of a major depressive episode within the third trimester of pregnancy or within 4 weeks following delivery as measured by the MINI (Mini International Neuropsychiatric Interview).
  • Current mild-moderate depression as measured by the HAM-D (HAM-D score>13 and <24)
  • Women were </= to 6 months postpartum at the time of screening
  • Owns a smartphone (Anrdroid or iOS smartphone with a recent, supported operating system)
  • Available and committed to engage with the program and complete assessments for a 3-month duration
  • Able to read and write in English
  • U.S. resident

排除标准

  • HAM-D score ≥ 24 (severe depression)
  • Active psychosis
  • Suicidal attempt or ideation with a plan and intent to harm oneself during the current episode of PPD
  • History of (a) drug and/or alcohol abuse within the past 12 months (determined by self-report)
  • Current pregnancy or plans to become pregnant within the next 4 months
  • Fetal demise within the past 24 months
  • Previous Woebot user

结局指标

主要结局

Hamilton Depression Rating Scale for Depression (HAMD)

时间窗: Post-treatment at 8 weeks

The HAMD is a 17-item, clinician rated measure of depression. Each item is scored from 0 to 2 and assesses the following criteria: insomnia, somatic symptoms, genital symptoms, loss of weight, and insight. The total score is calculated as a sum and ranges from 0 to 52, with higher scores indicating a greater degree of depression. The HAMD is commonly used for diagnostic purposes in research; structured clinical interviews such as this are recommended to actually diagnose clinical depression. It will be the primary outcome measure.

次要结局

  • Clinical Characteristic Questions(Baseline, Post-treatment at 8 weeks)
  • The Patient Health Questionnaire (PHQ-8)(Baseline, Mid-Treatment at 4 weeks, Post-treatment at 8 weeks, 1-Month Follow-up at 12 weeks)
  • Generalized Anxiety Disorder 2-item scale (GAD-2)(Baseline, Mid-Treatment at 4 weeks, Post-treatment at 8 weeks, 1-Month Follow-up at 12 weeks)
  • The Mother-to-Infant Bonding Scale (MIB)(Baseline, Mid-Treatment at 4 weeks, Post-treatment at 8 weeks, 1-Month Follow-up at 12 weeks)
  • Patient-Reported Outcomes Measurement Information System (PROMIS)(Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline from12 weeks)
  • The Edinburgh Postnatal Depression Scale (EPDS)(Baseline, Mid-Treatment at 4 weeks, Post-treatment at 8 weeks, 1-Month Follow-up at 12 weeks)
  • The Mental Health Self-Efficacy Scale (MHSES)(Baseline, Mid-Treatment at 4 weeks, Post-treatment at 8 weeks, 1-Month Follow-up at 12 weeks)
  • The Client Satisfaction Questionnaire (CSQ-8)(Post-treatment at 8 weeks)

研究者

发起方
Woebot Health
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验